The facts that the ARB drugs block the angiotensin II receptors and affect the functionalities of the renin-angiotensin system, point to the possibility that ARBs may curb the angiogenesis-promoting activities of the system, and consequently exert their effects on cancer cell growth and proliferation. Here, REN is linked to cancer.